HOME >> BIOLOGY >> NEWS
Bacteria's natural foe fights drug-resistant infections

in nursing homes and day-care centers, where drug-resistant strains thrive.

Until now, there has been no strategy to remove the reservoir of S. pneumoniae from the noses and throats of humans. Yet, this "home base" provides an excellent target for controlling infections.

"This enzyme will kill pneumococci on mucous membranes within seconds," says Jutta Loeffler, M.D., first author of the paper and a postdoctoral fellow at Rockefeller. "By treating individuals carrying this bacterium with the enzyme, you could significantly reduce the reservoir of these bugs in the population and consequently reduce infection rates."

Such a decline in the number of worldwide infections would lessen the need for traditional antibiotics and subsequently ease the mounting drug-resistance problem.

Bacteriophage, or phage, can be found just about anywhere: in sewage and soil and any other locations where bacteria are found. As part of their normal lifecycle, these tiny viruses infect, replicate, then burst out of bacteria before infecting their next host.

Special phage enzymes, which punch holes in the bacterial cell wall, ensure the phage a rapid exit; without this outer layer of protection the bacteria essentially cannot hold themselves together, and, they explode.

Fischetti discovered that the phage enzymes also work when applied to the outside of the bacterial cells: by adding a few drops of phage enzyme to a test tube of millions of bacteria, he found that he could kill nearly all of them within a few seconds.

Because phage enzymes are specific for the species or strain of bacterium from which they were produced, cultivating a tailor-made killer for any bacterium of interest may be possible. Last February, for example, Fischetti and colleagues reported the isolation of a phage enzyme specific for Group A streptococci, an infectious pathogen that causes strep throat and flesh-eating disease. Human clinical trials testing the
'"/>

Contact: Whitney Clavin
clavinw@rockefeller.edu
212-327-7900
Rockefeller University
6-Dec-2001


Page: 1 2 3 4

Related biology news :

1. Bacterias iron-absorbing mechanisms may open gates for new types of antibiotics
2. Posters highlight water, energy and other natural resource research
3. Hunting illusive signs of natural selection
4. University of Arizona licenses patent for natural fungicide
5. Improving crops without genetic modification natural variation holds the key
6. Using statistics to decipher secrets of natural mutation
7. New designed paclitaxel analog kills more cancer cells than natural product
8. After natural disasters, the risk of infection, epidemics from dead bodies is negligible
9. Pearly mussels: One of North Americas natural jewels is disappearing
10. Unnatural light-dark cycles expose duelling circadian clocks
11. St. Jude researchers create image of enzyme that orchestrates natural genetic engineering

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bacteria natural foe fights drug resistant infections

(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
(Date:2/12/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED METHOD AND SYSTEM TO IMPROVE ... further establishes NXT-ID,s position in the emerging "Internet of ... ability for multiple devices to collaborate with one another ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... Woodbridge, NJ (PRWEB) February 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... in a trade secrets lawsuit against Genewiz Inc. in ... illegally obtained and utilized GenScript’s trade secrets, and that ... The court entered an order denying motions for ...
(Date:2/26/2015)... February 26, 2015 Already well respected ... line by expanding its Length Gauge offerings with new ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length ... specification. Two new 1Vpp, 12mm stroke length variants ... applications. One is a variant with a weak spring, ...
(Date:2/26/2015)... 26, 2015 Regis Technologies announced ... of oncology drug substances. , Regis Technologies is proud ... new Potent Compound Suite (PCS) for 2015. , Regis ... foot, cGMP facility in Morton Grove, Illinois. The PCS ... potent compounds up to about one kilogram per batch. ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
Cached News: